Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25067265 | 0.95 | TLR8 (0.59) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL5824074 | 0.93 | TLR8 (0.57) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL18250324 | 0.93 | TLR8 (0.57) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL28078170 | 0.93 | TLR8 (0.57) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL15014467 | 0.89 | SMN1; SMN2 (0.60) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL27721562 | 0.86 | KMT2A (0.56) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL4396001 | 0.84 | SMN1; SMN2 (0.55) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL25857294 | 0.84 | SMN1; SMN2 (0.55) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL25067256 | 0.84 | SMN1; SMN2 (0.55) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 | |
| SCHEMBL3307602 | 0.83 | ALDH1A1 (0.53) | ALDH1A1POLBKMT2ASMN1; SMN2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129982-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| US-20230212629-A1 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-07-06 | — | — | US | disclosed |
| US-20230212629-A1 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-07-06 | — | — | US | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| CN-102216298-B | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR INC | 2014-04-16 | — | — | CN | disclosed |
| CN-102216298-A | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR | 2011-10-12 | — | — | CN | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | ALDH1A1 1168/4885POLB 660/4885KMT2A 1997/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | ALDH1A1 2378/4885POLB 2305/4885KMT2A 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.